Moderating the effect of endotoxins

Bibliographic Details
Title: Moderating the effect of endotoxins
Document Number: 20060292171
Publication Date: December 28, 2006
Appl. No: 10/595396
Application Filed: October 13, 2004
Abstract: The present invention relates to the use of an oral composition comprising yeast extract, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of the gut epithelial cells and diarrhoea as well as other COX-2 mediated effects.
Inventors: Corthesy-Theulaz, Irene (Epalinges, CH); Fotopoulos, Grigorios (Romont, CH); Bergonzelli, Gabriela (Bussigny-Pres Lausanne, CH)
Assignees: NESTEC S.A. (Vevey, CH)
Claim: 1. Use of yeast extract in the manufacture of an oral composition to treat the effects of infection by enterotoxin-producing pathogens.
Claim: 2. The use of claim 1 wherein the effects include failure of gut epithelial integrity, diarrhoea and other COX-2 mediated effects.
Claim: 3. The use of claim 1 or 2 wherein the pathogen is Clostridium difficile, Clostridium perfringens, E. coli, Leishmania donovani, Vibrio cholera, Salmonella typhimurium, Shingellae, Aeromonas hydrophila, Staphylococcus aureus, and/or enterotoxigenic Bacteroides fragilis.
Claim: 4. The use of any preceding claim wherein the oral composition comprises from 0.01 to 0.5% by volume of yeast extract.
Claim: 5. The use of any preceding claim wherein the oral composition further comprises peptones, preferably in an amount of from 0.3 to 7% by volume.
Claim: 6. The use of claim 5, wherein the peptones are hydrolysates of whey protein with an average peptide size of not greater than 5 amino acids.
Claim: 7. The use of any preceding claim wherein the oral composition further comprises meat extract, preferably in an amount of from 0.3 to 7% by volume.
Claim: 8. The use of any preceding claim wherein the oral composition is an adjuvant to a medicinal treatment.
Claim: 9. The use of any preceding claim wherein the oral composition is an infant formula or an enteral composition.
Current U.S. Class: 424195/160
Current International Class: 61
Accession Number: edspap.20060292171
Database: USPTO Patent Applications
More Details
Language:English